Search Results

You are looking at 1 - 10 of 906 items for :

  • "malignancy" x
Clear All
Full access

David S. Ettinger, Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Ramaswamy Govindan, Frederic W. Grannis Jr., Thierry Jahan, David H. Johnson, Anne Kessinger, Ritsuko Komaki, Feng-Ming Kong, Mark G. Kris, Lee M. Krug, Quynh-Thu Le, Inga T. Lennes, Renato Martins, Janis O'Malley, Raymond U. Osarogiagbon, Gregory A. Otterson, Jyoti D. Patel, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Scott J. Swanson, Douglas E. Wood and Stephen C. Yang

. NCCN Clinical Practice Guidelines in Oncology : Thymic Malignancies Version 2.2010, 02-23-10 ©2010 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the

Full access

Frank C. Detterbeck

spanning several decades reveals that no significant progress has been achieved. 1 The treatment of thymic malignancies has been largely empiric. A review of published studies from 1989 through 2009 found that only 5% involved cohorts of greater than 100

Full access

Maxim Norkin and John R. Wingard

Because of prolonged neutropenia and severe immunosuppression, patients with hematologic malignancies (HMs) and hematopoietic stem cell transplant (HSCT) recipients are at high risk for invasive fungal infections (IFIs), which are associated with

Full access

Nicolas C. Issa and Lindsey R. Baden

for patients with hematologic malignancies, including HCT recipients. Describe some important considerations regarding timing of administration, safety, and efficacy of currently available vaccines. Vaccination, along with appropriate infection

Full access

Rachel A. Bender Ignacio, Lilie L. Lin, Lakshmi Rajdev and Elizabeth Chiao

Since the advent of combination antiretroviral therapy (ART), malignancies have become among the leading causes of death in persons living with HIV (PLWH). 1 As treatment outcomes for PLWH and malignancies have improved in the past 2 decades

Full access

Constantine S. Mitsiades and Kenneth C. Anderson

agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies . Blood 2004 ; 103 : 1635 - 1640 . 80. Muller-Thomas C Schuster T Peschel C Gotze KS . A limited number of 5-azacitidine cycles can be effective treatment in MDS

Full access

Robert Swarm, Amy Pickar Abernethy, Doralina L. Anghelescu, Costantino Benedetti, Craig D. Blinderman, Barry Boston, Charles Cleeland, Nessa Coyle, Oscar A. deLeon-Casasola, June G. Eilers, Betty Ferrell, Nora A. Janjan, Sloan Beth Karver, Michael H. Levy, Maureen Lynch, Natalie Moryl, Barbara A. Murphy, Suzanne A. Nesbit, Linda Oakes, Eugenie A. Obbens, Judith A. Paice, Michael W. Rabow, Karen L. Syrjala, Susan Urba and Sharon M. Weinstein

-related pain is distinct from pain experienced by patients without malignancies. Pain occurs in approximately one quarter of patients with newly diagnosed malignancies, one third of patients undergoing treatment, and three quarters of patients with advanced

Full access

Sophia Koo and Lindsey R. Baden

-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010 . Blood 2005 ; 106 : 1538 – 1543 . 5. Boue F Gabarre J Gisselbrecht C . Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma . J Clin Oncol 2006 ; 24

Full access

Tanya M. Wildes, Derek L. Stirewalt, Bruno Medeiros and Arti Hurria

HCT Discuss the safety and efficacy of HCT in older patients with hematologic malignancies Summarize the role of CGA in the selection of patients for HCT The incidence of most hematologic malignancies increases with age. 1 - 3 With the aging

Full access

Jeffrey F. Moley

in all patients with multiple endocrine neoplasia type 2 (MEN 2) syndromes (25% of cases). Second, although MTC is more aggressive than differentiated thyroid carcinoma, it is still an indolent malignancy, with reported 10-year survival rates from 69